1. Home
  2. COLL vs PAHC Comparison

COLL vs PAHC Comparison

Compare COLL & PAHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • PAHC
  • Stock Information
  • Founded
  • COLL 2002
  • PAHC 1946
  • Country
  • COLL United States
  • PAHC United States
  • Employees
  • COLL N/A
  • PAHC N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • PAHC Biotechnology: Pharmaceutical Preparations
  • Sector
  • COLL Health Care
  • PAHC Health Care
  • Exchange
  • COLL Nasdaq
  • PAHC Nasdaq
  • Market Cap
  • COLL 958.8M
  • PAHC 968.3M
  • IPO Year
  • COLL 2015
  • PAHC 2014
  • Fundamental
  • Price
  • COLL $30.13
  • PAHC $25.61
  • Analyst Decision
  • COLL Strong Buy
  • PAHC Sell
  • Analyst Count
  • COLL 4
  • PAHC 4
  • Target Price
  • COLL $43.75
  • PAHC $21.25
  • AVG Volume (30 Days)
  • COLL 287.8K
  • PAHC 235.7K
  • Earning Date
  • COLL 08-07-2025
  • PAHC 05-07-2025
  • Dividend Yield
  • COLL N/A
  • PAHC 1.89%
  • EPS Growth
  • COLL N/A
  • PAHC 140.17
  • EPS
  • COLL 1.25
  • PAHC 0.78
  • Revenue
  • COLL $664,283,000.00
  • PAHC $1,190,682,000.00
  • Revenue This Year
  • COLL $20.04
  • PAHC $28.33
  • Revenue Next Year
  • COLL $3.98
  • PAHC $13.78
  • P/E Ratio
  • COLL $23.59
  • PAHC $32.60
  • Revenue Growth
  • COLL 17.17
  • PAHC 19.12
  • 52 Week Low
  • COLL $23.23
  • PAHC $16.16
  • 52 Week High
  • COLL $42.29
  • PAHC $26.55
  • Technical
  • Relative Strength Index (RSI)
  • COLL 55.25
  • PAHC 67.45
  • Support Level
  • COLL $29.11
  • PAHC $24.59
  • Resistance Level
  • COLL $30.30
  • PAHC $25.37
  • Average True Range (ATR)
  • COLL 0.71
  • PAHC 0.74
  • MACD
  • COLL -0.03
  • PAHC -0.01
  • Stochastic Oscillator
  • COLL 44.32
  • PAHC 97.23

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Share on Social Networks: